Related Experiment Video
Updated: Jul 3, 2026

Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin
Published on: May 6, 2018
mToR inhibitors-induced proteinuria: mechanisms, significance, and management
Emmanuel Letavernier1, Christophe Legendre
1Transplantation Unit, Hôpital Necker, 75743 Paris, France. emmanuel.letavernier@tnn.ap-hop-paris.fr
Abstract:
Massive urinary protein excretion has been observed after conversion from calcineurin inhibitors to mammalian target of rapamycin (mToR) inhibitors, especially sirolimus, in renal transplant recipients with chronic allograft nephropathy. Because proteinuria is a major predictive factor of poor transplantation outcome, many studies focused on this adverse event during the past years. Whether proteinuria was due to sirolimus or only a consequence of calcineurin inhibitors withdrawal remained unsolved until high range proteinuria has been observed during sirolimus therapy in islet transplantation and in patients who received sirolimus de novo. Podocyte injury and focal segmental glomerulosclerosis have been related to mToR inhibition in some patients, but the pathways underlying these lesions remain hypothetic. We discuss herein the possible mechanisms and the significance of mToR blockade-induced proteinuria.
Insights
Mammalian target of rapamycin (mToR) inhibitors, like sirolimus, can cause significant proteinuria in kidney transplant patients. This review explores the mechanisms and implications of mToR inhibitor-induced proteinuria.
Area of Science:
- Nephrology
- Transplantation Immunology
- Pharmacology
Background:
- Massive urinary protein excretion is a known issue in renal transplant recipients converting from calcineurin inhibitors to mammalian target of rapamycin (mToR) inhibitors, particularly sirolimus.
- Proteinuria is a significant predictor of poor outcomes in kidney transplantation, prompting extensive research into its causes.
Purpose of the Study:
- To investigate the causal link between sirolimus therapy and proteinuria, distinguishing it from calcineurin inhibitor withdrawal.
- To explore the potential mechanisms and clinical significance of proteinuria induced by mToR inhibitors.
Main Methods:
- Review of existing literature on proteinuria in renal transplant recipients treated with mToR inhibitors.
- Analysis of cases involving sirolimus therapy in islet transplantation and de novo treatment.
Main Results:
- High-level proteinuria has been observed during sirolimus therapy in various contexts, suggesting a direct effect of the drug.
- Podocyte injury and focal segmental glomerulosclerosis have been associated with mToR inhibition, though underlying pathways require further elucidation.
Conclusions:
- mToR inhibitor-induced proteinuria is a distinct clinical event, not solely a consequence of calcineurin inhibitor withdrawal.
- Understanding the mechanisms of mToR blockade-induced proteinuria is crucial for managing transplant outcomes.
Related Concept Videos
Nephrotic Syndrome II : Assessment and Medical Management
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Urinary Tract Calculi III: Medical Management
Antihypertensive Drugs: Direct Renin Inhibitors
Acute Kidney Injury II: Pathophysiology
